Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 102 results for kidney cancer

  1. Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis (TA959)

    Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.

  2. Medical technologies advisory committee members

    diagnostics and technology accelerator. Katherine's academic background is cancer genetics (PhD, University of Dundee) and molecular...

  3. Suspected sepsis: recognition, diagnosis and early management (NG51)

    This guideline covers the recognition, diagnosis and early management of suspected sepsis. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.

  4. Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management (NG240)

    This guideline covers recognising, diagnosing and managing bacterial meningitis and meningococcal disease in babies, children, young people and adults. It aims to reduce death and disability by helping healthcare professionals recognise meningitis and treat it quickly and effectively.

  5. COVID-19 rapid guideline: managing COVID-19 (NG191)

    This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.

  6. NICE and health inequalities

    Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged

  7. Supporting the health and care system in improving productivity

    Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.

  8. Committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  9. Developing NICE guidelines: the manual (PMG20)

    Developing NICE guidelines: the manual

  10. 1.4 million more people at risk of severe COVID-19 to have access to antiviral Paxlovid

    A further 1.4 million people who have an increased risk for progression to severe COVID-19 will be eligible for Paxlovid if they test positive following updated NICE final draft guidance published today (11 January 2024).

  11. Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer (TA944)

    Evidence-based recommendations on durvalumab (Imfinzi) with gemcitabine and cisplatin for treating locally advanced, unresectable, or metastatic biliary tract cancer in adults.

  12. Past appeals and decisions

    for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945] 3 September 2020 TBC Afamelanotide for treating...

  13. Suspected neurological conditions: recognition and referral (NG127)

    This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.

  14. Urinary incontinence in neurological disease: assessment and management (CG148)

    This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.

  15. Tixagevimab plus cilgavimab for preventing COVID-19 (TA900)

    Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.